Migraine News and Research

Latest Migraine News and Research

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

Public disclosure of Bachmann's migraine condition raises much-needed awareness

University of Vermont Professor of Neurology and migraine expert Robert Shapiro, M.D., Ph.D., says U.S. Representative and presidential candidate Michele Bachmann's public disclosure of her migraine condition has brought much-needed awareness to this disabling, often-stigmatized disorder, which afflicts millions of Americans.

21 Jul 2011

Study examines cost-effectiveness of MS drugs in the U.S.

A new study examining the cost-effectiveness of drugs to treat multiple sclerosis (MS) in the United States finds that the health gains from these drugs come at a very high cost compared to basic therapy to control the symptoms of MS and compared to treatments for other chronic diseases.

21 Jul 2011

Scientists analyze structural changes in calcium channels caused by Timothy-mutation

The human genome encodes 243 voltage-gated ion channels. Mutations in calcium channels can cause severe inherited diseases such as migraine, night blindness, autism spectrum disorders and Timothy syndrome, which leads to severe cardiovascular disorders.

15 Jul 2011

Maintaining general health may help reduce risk for dementia

Improving and maintaining health factors not traditionally associated with dementia, such as denture fit, vision and hearing, may lower a person's risk for developing dementia, according to a new study published in the July 13, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology.

14 Jul 2011

UW scientists determine atomic architecture of sodium channel

Scientists at the University of Washington (UW) in Seattle have determined the atomic architecture of a sodium channel. The achievement opens new possibilities for molecular medicine researchers around the world in designing better drugs for pain, epilepsy, and heart rhythm disturbances.

14 Jul 2011

FDA clears St. Jude Medical's Epiducer lead delivery system for neurostimulation

St. Jude Medical, Inc., a global medical device company, today announced the U.S. Food and Drug Administration (FDA) clearance and limited market release of the Epiducer lead delivery system for neurostimulation therapy.

13 Jul 2011

Osteoporosis, low bone density common in people with early-stage MS

Osteoporosis and low bone density are common in people in the early stages of multiple sclerosis (MS), according to a new study published in the July 12, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

12 Jul 2011

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

St. Jude Medical, Inc., a global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for expansion of its BROADEN (BROdmann Area 25 DEep brain Neurostimulation) study for depression. This expansion will allow a maximum of 20 sites across the U.S. to enroll up to 125 patients.

11 Jul 2011

Study links OBEs with neural instability and errors in body representation

Although out-of-body experiences (OBEs) are typically associated with migraine, epilepsy and psychopathology, they are quite common in healthy and psychologically normal individuals as well. However, they are poorly understood.

11 Jul 2011

Research roundup: Rural hospitals have poorer quality; Cost-effective migraine relief; Doctors still take Medicare

Quality Of Care And Patient Outcomes In Critical Access Rural Hospitals -- This study looks at the quality of care provided by patterns of care at "critical access hospitals," a federal designation for hospitals that serve rural populations and thus have been granted special incentives under Medicare.

8 Jul 2011

Study: Breastfeeding does not appear to protect women from MS relapses

New research finds breastfeeding doesn't appear to protect against multiple sclerosis (MS) relapses, despite previous studies suggesting there may be a protective role. The research is published in the July 6, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Jul 2011

Treating migraines with behavioral approaches can make financial sense

Treating chronic migraines with behavioral approaches - such as relaxation training, hypnosis and biofeedback - can make financial sense compared to prescription-drug treatment, especially after a year or more, a new study found.

6 Jul 2011

NUROMOL non-prescription painkiller now available in pharmacies across the UK

A new non-prescription painkiller is now available in pharmacies across the UK, heralding the first UK painkiller combination of ibuprofen and paracetamol in 'over-the-counter' pain relief.

28 Jun 2011

Scientists identify central switch responsible for epilepsy

UC Irvine and French researchers have identified a central switch responsible for the transformation of healthy brain cells into epileptic ones, opening the way to both treat and prevent temporal lobe epilepsy.

28 Jun 2011

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Omeros Corporation today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells.

27 Jun 2011

Positive preliminary findings from ATI's neurostimulation system study on cluster headache

Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable system for severe headaches, today announced positive preliminary findings from a study evaluating the safety and efficacy of the company's investigational neurostimulation system for the treatment of cluster headache.

27 Jun 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

MAP to present LEVADEX data on migraine at 15th Congress of IHC

MAP Pharmaceuticals, Inc. today announced that LEVADEX orally inhaled migraine drug will be featured in four poster presentations, including one late-breaker presentation, at the 15th Congress of the International Headache Society (IHC) in Berlin, Germany on June 23-26, 2011.

23 Jun 2011

New sAPPβ biomarker may identify people at risk of developing Alzheimer's

A new biomarker may help identify which people with mild memory deficits will go on to develop Alzheimer's disease, according to a new study published in the June 22, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

23 Jun 2011